SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing

SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing
Martinsried/Munich, Germany, February 8, 2010 -- SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced that Dr. Robert Phelps has joined the Company as Head of Business Development & Licensing.


Most recently, Dr. Phelps has been Director Business Development & Licensing at PARI Pharma GmbH, Munich, Germany, where he was responsible for all in- and out-licensing activities pertaining to the company's aerosol delivery technologies and pharmaceutical development programs. Previous to that, he has held business development and licensing positions at various biotechnology and pharmaceutical companies such as Bavarian Nordic A/S, Patheon UK Ltd., Evotec AG, and Hexal Gentech ForschungsGmbH. He received his PhD in 1997 in biochemistry from the University of Frankfurt and the Paul-Ehrlich-Institut in Germany. Subsequently, he held a research position as a post-doctoral fellow at the Medical University of South Carolina, Charleston (SC), USA, until 1999.


"Robert is an accomplished, skilled executive with more than ten years experience in business development and licensing in the biotech and pharma industry," said Dr. Peter Buckel, CEO of SuppreMol. "He will be a valuable addition to our team as we have reached a stage with excellent development and marketing opportunities for our lead product SM101. Besides, we are also planning an expansion of our pipeline by acquisitions or in-licensing."


"I am very happy to join SuppreMol," Dr. Robert Phelps added. "The Company has been highly successful in securing substantial funds and advancing its products to the clinic. Already, various potential corporate partners have expressed great interest in SuppreMol's product candidates."

 

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.